{"entity":{"id":"nct04417621","kind":"trial","name":"Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma","aka":[],"tldr":"A phase 2 trial of Naporafenib, Trametinib, Ribociclib in melanoma, run by Novartis Pharmaceuticals, active and no longer recruiting.","summary":"Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma is a phase 2 interventional study registered as NCT04417621 by Novartis Pharmaceuticals, with 134 participants enrolled, started 2020-10-30 and due to reach its primary completion in 2027-02-02. Interventions recorded: LXH254, LTT462, Trametinib, Ribociclib. Conditions listed: Melanoma. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04417621","url":"https://clinicaltrials.gov/study/NCT04417621"}],"tags":["ctgov-ingest"],"related":[],"cancers":["melanoma","advanced-melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":["naporafenib","trametinib","ribociclib"],"companies":["novartis"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04417621","phase":"2","setting":"A Randomized, Open-label, Multi-arm, Two-part, Phase II Study to Assess Efficacy and Safety of Multiple LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic BRAFV600 or NRAS Mutant Melanoma","sponsor":"Novartis Pharmaceuticals","participation":[{"nct":"NCT04417621","source":"https://clinicaltrials.gov/study/NCT04417621","fetchedAt":"2026-10-07T16:53:19.953Z","studySha256":"d15d66f623cea51763b81bbd5421906e46588ecfa79e9f60d5258cc7bd46c3d3","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-03-12","leadSponsor":"Novartis Pharmaceuticals","collaboratorCount":0,"minimumAge":"12 Years","maximumAge":"120 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":134,"enrolmentType":"ACTUAL","siteCount":36,"recruitingSiteCount":0,"countries":["Argentina","Australia","Belgium","France","Germany","Israel","Italy","Netherlands","Norway","Switzerland","United Kingdom","United States"]}],"started":"2020-10-30","startedType":"actual","enrolled":134,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04417621/","neighbours":{"cancer":[{"id":"advanced-melanoma","kind":"cancer","name":"Advanced melanoma (unresectable stage III and stage IV)","route":"/cancers/advanced-melanoma/"},{"id":"braf-v600-melanoma","kind":"cancer","name":"BRAF V600-mutant melanoma","route":"/cancers/braf-v600-melanoma/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"drug":[{"id":"naporafenib","kind":"drug","name":"Naporafenib","route":"/drugs/naporafenib/"},{"id":"ribociclib","kind":"drug","name":"Ribociclib","route":"/drugs/ribociclib/"},{"id":"trametinib","kind":"drug","name":"Trametinib","route":"/drugs/trametinib/"}],"company":[{"id":"novartis","kind":"company","name":"Novartis","route":"/companies/novartis/"}]}}